Abstract for Biomed Israel 2023

**Targeting Aging and senescence with molecular therapeutics**

Michelle Mahler, MD, CMO 1 E therapeutics

1E Therapeutics is a breakthrough drug- development company, creating a novel class of programmable oligonucleotide therapeutics, designed to treat humanity’s most intractable diseases by autonomously and precisely silencing disease-causing RNAs in human or pathogen cells

Our groundbreaking and patented platform is uniquely able to create potentially safer and more targeted that address chronic and life threatening indications as well as emerging and evolving pathogens.

We have the potential to address a broad series of disorders across multiple therapeutic areas.

I will be sharing my thoughts on approaches to drug development for age related diseases.

Aging is not a regulatory diagnosis but there are many diseases, which are associated with aging and impact longevity and quality of life. Furthermore, due to difficulties in quantifying individual age related diseases, which affect specific organ systems, and have complex biology is challenging in drug development. I believe an approach with clear demonstration of the unmet medical need, robust clinical endpoints, the use of biomarkers and demonstration of benefit vs. risk is required to gain regulatory approval. Taking a step- wise approach with multiple diseases using a singular pathway is one mechanism to gain a broad disease agnostic regulatory approval.